ProPharma Group announces the appointment of Bryan Katz as Chief Strategy Officer (CSO) / Head of Corporate Development
“Bryan’s broad knowledge and technical expertise within the life sciences industry will provide an invaluable advantage as we explore strategic opportunities at all levels of the organization.”Michael StombergProPharma Group’s CEO
September 13, 2022
With over 20 years of proven and progressive leadership experience within the biopharmaceutical and life sciences industry, Bryan joins ProPharma Group from Syneos Health, where he most recently served as Senior Vice President, Global Solution Development Lead. During his tenure at Syneos Health, Bryan led new product innovation in the emerging biopharmaceutical and biotechnology segments, focusing on the design, incubation and introduction of new solutions that improve the viability and accessibility of new therapies. A United States Navy, Bryan earned his MBA from the Kellogg School of Management at Northwestern University, where he also earned his BS in Chemical Engineering, specializing in process dynamics and control. Bryan’s depth of experience is invaluable in achieving ProPharma Group’s mission and overarching goal of improving patient health and safety.
In addition to Bryan’s role as chief strategy officer, he will be responsible for corporate development, where he will lead ProPharma Group’s mergers and acquisitions strategy. Joining PPG at a time of great organic momentum, Bryan will align the company’s strategic business and investment priorities to accelerate ProPharma Group’s growth initiatives.
“We are delighted to welcome Bryan Katz as our new Chief Strategy Officer and Chief Business Development Officer,” said Michael Stomberg, CEO of ProPharma Group. “Bryan’s expertise will enable ProPharma Group to further accelerate its growth strategy, both organically and through acquisition. Bryan’s vast knowledge and technical expertise within the life sciences industry will provide an invaluable advantage as we explore strategic opportunities at all levels of the organization. »
“I am thrilled to join ProPharma Group and bring a fresh perspective to the company’s strategic vision,” said Bryan Katz. “The go-to-market strategy for global CROs is constantly evolving and ProPharma Group has a tremendous opportunity to explore new avenues to capitalize on our competitive advantages and innovative solutions. I look forward to working with ProPharma Group’s talented management team to drive initiatives rooted in their unique strategic vision of continued and sustainable growth.
About ProPharma Group
ProPharma Group is the global, independent and single provider of regulatory, clinical and compliance services serving pharmaceutical, biotechnology and medical device companies. Founded in 2001, ProPharma Group has more than 2,500 colleagues worldwide who provide solutions to complex challenges in a dynamic regulatory environment. With a mission to improve patient health and safety, ProPharma Group is focused on providing the highest quality services throughout the complete product life cycle, including regulatory sciences, clinical research solutions , life science consulting, pharmacovigilance and medical information services. For more information, please visit http://www.propharmagroup.com.
About Odyssey Investment Partners
Odyssey Investment Partners, with offices in New York and Los Angeles, is a leading private equity investment firm with over 25 years of experience partnering with skilled managers to transform middle market companies into more efficient and diversified businesses with strong growth profiles. Odyssey makes majority controlled investments in industries with positive long-term prospects and favorable secular trends. For more information on Odyssey, please visit http://www.odysseyinvestment.com.
Share the article on social networks or by e-mail: